OUTLOOK THERAPEUTICS INC is trading 18.2% up at $1.30 following a significant price-target hike from Ascendiant Capital and continued positive momentum from its recent FDA filing.

  • Ascendiant Capital reiterated its Buy rating and raised its price target from $6 to $10, signaling substantial upside potential.
  • The stock's rally is also fueled by the recent resubmission of its Biologics License Application (BLA) to the FDA for ONS-5010.
  • This builds on strong gains from the previous sessions as investor sentiment remains highly positive around the company's regulatory and commercial prospects.